본문 바로가기
KERD
논문KCI 등재

Autoimmune Hepatitis: 2019 Update

Atsushi Tanaka
거트앤리버 소화기연관학회협의회|2020.07|Gut and Liver|제14권 제4호|pp. 430-438|DOI 10.5009/gnl19261

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Health-related quality of lifeEpidemiologyClinical trialEnvironmental factorsImmunosuppressive agents

초록

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease, characterized by the elevation of aminotransferases, presence of anti-nuclear antibody or anti-smooth muscle antibody, elevated immunoglobulin G (IgG), and interface hepatitis/plasma-lymphocytic inflammation based on histology. Recent epidemiological studies have indicated an increasing trend in the prevalence of AIH worldwide, especially in male patients; this trend may suggest the alteration of environmental triggers of disease onset over time. As no disease-specific biomarker or histological finding is currently available, AIH requires a clinical diagnosis, and a validated diagnostic scoring system with acceptable specificity and sensitivity has been proposed. Regarding treatment, corticosteroids and azathioprine are recommended, and in those who exhibit an incomplete response or those who are intolerant to these drugs, second-line therapy, such as mycophenolate mofetil, is considered. Overall, the long-term outcome is excellent in patients with complete biochemical responses, while life-long maintenance treatment may be required since the cessation of immunosuppressive agents frequently leads to the relapse of the disease. Acute-onset AIH does occur, and the diagnosis is very challenging due to the lack of serum autoantibodies or elevated IgG. The unmet needs include earlier diagnosis, intervention with disseminated clinical practice guidelines, and recognition and improvement of patients’ health-related quality of life with the development of novel corticosteroid-free treatment regimens.

Abstract

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease, characterized by the elevation of aminotransferases, presence of anti-nuclear antibody or anti-smooth muscle antibody, elevated immunoglobulin G (IgG), and interface hepatitis/plasma-lymphocytic inflammation based on histology. Recent epidemiological studies have indicated an increasing trend in the prevalence of AIH worldwide, especially in male patients; this trend may suggest the alteration of environmental triggers of disease onset over time. As no disease-specific biomarker or histological finding is currently available, AIH requires a clinical diagnosis, and a validated diagnostic scoring system with acceptable specificity and sensitivity has been proposed. Regarding treatment, corticosteroids and azathioprine are recommended, and in those who exhibit an incomplete response or those who are intolerant to these drugs, second-line therapy, such as mycophenolate mofetil, is considered. Overall, the long-term outcome is excellent in patients with complete biochemical responses, while life-long maintenance treatment may be required since the cessation of immunosuppressive agents frequently leads to the relapse of the disease. Acute-onset AIH does occur, and the diagnosis is very challenging due to the lack of serum autoantibodies or elevated IgG. The unmet needs include earlier diagnosis, intervention with disseminated clinical practice guidelines, and recognition and improvement of patients’ health-related quality of life with the development of novel corticosteroid-free treatment regimens.

참고문헌 (86)

  1. Manns MP, "Autoimmune hepatitis : update 2015", J Hepatol, 62(1 Suppl), pp.S100~S111 (2015)
  2. Floreani A, "Etiopathogenesis of autoimmune hepatitis", J Autoimmun, 95, pp.133~143 (2018)
  3. Alvarez F, "International Autoimmune Hepatitis Group report : review of criteria for diagnosis of autoimmune hepatitis", J Hepatol, 31, pp.929~938 (1999)
  4. Hennes EM, "Simplified criteria for the diagnosis of autoimmune hepatitis", Hepatology, 48, pp.169~176 (2008)
  5. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : autoimmune hepatitis", J Hepatol, 63, pp.971~1004 (2015)
  6. Wang Z, "The management of autoimmune hepatitis patients with decompensated cirrhosis : real-world experience and a comprehensive review", Clin Rev Allergy Immunol, 52, pp.424~435 (2017)
  7. Yoshizawa K, "Long-term outcome of Japanese patients with type 1 autoimmune hepatitis", Hepatology, 56, pp.668~676 (2012)
  8. Kim BH, "Populationbased prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea", PLoS One, 12, pp.e0182391~ (2017)
  9. Takahashi A, "Autoimmune hepatitis in Japan : trends in a nationwide survey", J Gastroenterol, 52, pp.631~640 (2017)
  10. Kim BH, "Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea : a nationwide, multicenter study", J Gastroenterol Hepatol, 28, pp.128~134 (2013)
  11. Danielsson Borssén Å, "Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis", Scand J Gastroenterol, 52, pp.1022~1028 (2017)
  12. Delgado JS, "Autoimmune hepatitis in southern Israel : a 15-year multicenter study", J Dig Dis, 14, pp.611~618 (2013)
  13. Grønbæk L, "Autoimmune hepatitis in Denmark : incidence, prevalence, prognosis, and causes of death : a nationwide registry-based cohort study", J Hepatol, 60, pp.612~617 (2014)
  14. Haider AS, "Autoimmune hepatitis in a demographically isolated area of Australia", Intern Med J, 40, pp.281~285 (2010)
  15. Ngu JH, "Population-based epidemiology study of autoimmune hepatitis : a disease of older women", J Gastroenterol Hepatol, 25, pp.1681~1686 (2010)
  16. Puustinen L, "Incidence, prevalence, and causes of death of patients with autoimmune hepatitis : a nationwide register-based cohort study in Finland", Dig Liver Dis, 51, pp.1294~1299 (2019)
  17. van Gerven NM, "Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands", Scand J Gastroenterol, 49, pp.1245~1254 (2014)
  18. Werner M, "Epidemiology and the initial presentation of autoimmune hepatitis in Sweden : a nationwide study", Scand J Gastroenterol, 43, pp.1232~1240 (2008)
  19. Tanaka A, "Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan", Hepatol Res, 49, pp.881~889 (2019)
  20. Koay LB, "Type 1 autoimmune hepatitis in Taiwan : diagnosis using the revised criteria of the International Autoimmune Hepatitis Group", Dig Dis Sci, 51, pp.1978~1984 (2006)
  21. Grønbæk L, "Family occurrence of autoimmune hepatitis : a Danish nationwide registry-based cohort study", J Hepatol, 69, pp.873~877 (2018)
  22. de Boer YS, "Genome-wide association study identifies variants associated with autoimmune hepatitis type 1", Gastroenterology, 147, pp.443~452 (2014)
  23. Gurung A, "Histologic features of autoimmune hepatitis : a critical appraisal", Hum Pathol, 82, pp.51~60 (2018)
  24. Zeng T, "Noninvasive indices for monitoring disease course in Chinese patients with autoimmune hepatitis", Clin Chim Acta, 486, pp.135~141 (2018)
  25. Migita K, "Serum cytokine profiles and Mac-2 binding protein glycosylation isomer(M2BPGi)level in patients with autoimmune hepatitis", Medicine(Baltimore), 97, pp.e13450~ (2018)
  26. Wang J, "Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis", World J Gastroenterol, 23, pp.859~868 (2017)
  27. Hartl J, "Transient elastography in autoimmune hepatitis : timing determines the impact of inflammation and fibrosis", J Hepatol, 65, pp.769~775 (2016)
  28. Hartl J, "Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis", J Hepatol, 68, pp.754~763 (2018)
  29. Wu S, "Systematic review : diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis", Hepatol Int, 13, pp.91~101 (2019)
  30. Johnson PJ, "Meeting report : International Autoimmune Hepatitis Group", Hepatology, 18, pp.998~1005 (1993)
  31. Muratori P, "Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients", Hepatology, 49, pp.1782~1783 (2009)
  32. Yeoman AD, "Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group(IAIHG)criteria in acute and chronic liver disease", Hepatology, 50, pp.538~545 (2009)
  33. Arcos-Machancoses JV, "Accuracy of the simplified criteria for autoimmune hepatitis in children : systematic review and decision analysis", J Clin Exp Hepatol, 9, pp.147~155 (2019)
  34. Tanaka A, "Autoimmune liver diseases in the Asia-Pacific region : proceedings of APASL symposium on AIH and PBC 2016", Hepatol Int, 10, pp.909~915 (2016)
  35. Gordon V, "Diagnosis, presentation and initial severity of autoimmune hepatitis(AIH)in patients attending 28 hospitals in the UK", Liver Int, 38, pp.1686~1695 (2018)
  36. van den Brand FF, "Increased mortality among patients with vs without cirrhosis and autoimmune hepatitis", Clin Gastroenterol Hepatol, 17, pp.940~947 (2019)
  37. Borssén ÅD, "Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: a cohort study", Medicine (Baltimore), 96, pp.e7708~ (2017)
  38. Choi J, "Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country", Liver Int, 39, pp.985~994 (2019)
  39. Lamers MM, "Treatment options for autoimmune hepatitis : a systematic review of randomized controlled trials", J Hepatol, 53, pp.191~198 (2010)
  40. Manns MP, "Diagnosis and management of autoimmune hepatitis", Hepatology, 51, pp.2193~2213 (2010)
  41. Pape S, "Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 17, pp.2068~2075 (2019)
  42. Manns MP, "Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis", Gastroenterology, 139, pp.1198~1206 (2010)
  43. Lohse AW, "Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment", J Hepatol, 54, pp.837~839 (2011)
  44. Peiseler M, "Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 16, pp.260~267 (2018)
  45. Liberal R, "Expert clinical management of autoimmune hepatitis in the real world", Aliment Pharmacol Ther, 45, pp.723~732 (2017)
  46. Sievers TM, "Mycophenolate mofetil", Pharmacotherapy, 17, pp.1178~1197 (1997)
  47. Efe C, "Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis", Clin Gastroenterol Hepatol, 15, pp.1950~1956 (2017)
  48. De Lemos-Bonotto M, "A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment", Eur J Gastroenterol Hepatol, 30, pp.212~216 (2018)
  49. Santiago P, "Systematic review with meta-analysis : mycophenolate mofetil as a second-line therapy for autoimmune hepatitis", Aliment Pharmacol Ther, 49, pp.830~839 (2019)
  50. Dörner T, "Treatment of primary Sjögren’s syndrome with ianalumab(VAY736)targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity", Ann Rheum Dis, 78, pp.641~647 (2019)
  51. Adam R, "Evolution of indications and results of liver transplantation in Europe : a report from the European Liver Transplant Registry(ELTR)", J Hepatol, 57, pp.675~688 (2012)
  52. Singal AK, "Evolving frequency and outcomes of liver transplantation based on etiology of liver disease", Transplantation, 95, pp.755~760 (2013)
  53. The Japanese Liver Transplantation Society, "Liver transplantation in Japan : registry by the Japanese Liver Transplantation Society", Japanese J Transplant, 52, pp.134~147 (2015)
  54. Ayata G, "Liver transplantation for autoimmune hepatitis : a long-term pathologic study", Hepatology, 32, pp.185~192 (2000)
  55. Campsen J, "Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal", Liver Transpl, 14, pp.1281~1286 (2008)
  56. Duclos-Vallée JC, "A 10 year follow up study of patients transplanted for autoimmune hepatitis : histological recurrence precedes clinical and biochemical recurrence", Gut, 52, pp.893~897 (2003)
  57. González-Koch A, "Recurrent autoimmune hepatitis after orthotopic liver transplantation", Liver Transpl, 7, pp.302~310 (2001)
  58. Krishnamoorthy TL, "Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease", Liver Transpl, 22, pp.34~41 (2016)
  59. Milkiewicz P, "Recurrence of autoimmune hepatitis after liver transplantation", Transplantation, 68, pp.253~256 (1999)
  60. Molmenti EP, "Incidence and recurrence of autoimmune", alloimmune hepatitis in liver transplant recipients, 2002, pp.8, 519~526
  61. Montano-Loza AJ, "Risk factors for recurrence of autoimmune hepatitis after liver transplantation", Liver Transpl, 15, pp.1254~1261 (2009)
  62. Prados E, "Outcome of autoimmune hepatitis after liver transplantation", Transplantation, 66, pp.1645~1650 (1998)
  63. Ratziu V, "Long-term follow-up after liver transplantation for autoimmune hepatitis : evidence of recurrence of primary disease", J Hepatol, 30, pp.131~141 (1999)
  64. Reich DJ, "Liver transplantation for autoimmune hepatitis", Hepatology, 32(4 Pt 1), pp.693~700 (2000)
  65. Montano-Loza AJ, "Systematic review : recurrent autoimmune liver diseases after liver transplantation", Aliment Pharmacol Ther, 45, pp.485~500 (2017)
  66. Visseren T, "Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation", Best Pract Res Clin Gastroenterol, 31, pp.187~198 (2017)
  67. Balan V, "Long-term outcome of human leukocyte antigen mismatching in liver transplantation : results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database", Hepatology, 48, pp.878~888 (2008)
  68. Kerkar N, "De novo autoimmune hepatitis : is this different in adults compared to children", J Autoimmun, 95, pp.26~33 (2018)
  69. Kerkar N, "‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation : a comprehensive review", J Autoimmun, 66, pp.17~24 (2016)
  70. Takahashi H, "Acute presentation of autoimmune hepatitis : does it exist? A published work review", Hepatol Res, 41, pp.498~504 (2011)
  71. Muratori P, "Clinical and prognostic implications of acute onset of autoimmune hepatitis : an Italian multicenter study", Dig Liver Dis, 50, pp.698~702 (2018)
  72. Joshita S, "Clinical features of autoimmune hepatitis with acute presentation : a Japanese nationwide survey", J Gastroenterol, 53, pp.1079~1088 (2018)
  73. Abe K, "Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis", World J Hepatol, 4, pp.262~267 (2012)
  74. Hofer H, "Centrilobular necrosis in autoimmune hepatitis : a histological feature associated with acute clinical presentation", J Clin Pathol, 59, pp.246~249 (2006)
  75. Sonthalia N, "Natural history and treatment outcomes of severe autoimmune hepatitis", J Clin Gastroenterol, 51, pp.548~556 (2017)
  76. Nguyen Canh H, "Acute presentation of autoimmune hepatitis : a multicentre study with detailed histological evaluation in a large cohort of patients", J Clin Pathol, 70, pp.961~969 (2017)
  77. Anastasiou OE, "Corticosteroid therapy improves the outcome of autoimmune hepatitis-induced acute liver failure", Digestion, 98, pp.104~111 (2018)
  78. Shen Y, "Clinical and pathological characteristics of autoimmune hepatitis with acute presentation", Can J Gastroenterol Hepatol, 2018, pp.3513206~ (2018)
  79. Zachou K, "Prompt initiation of highdose i. v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis", Hepatol Res, 49, pp.96~104 (2019)
  80. Anand L, "Flare of autoimmune hepatitis causing acute on chronic liver failure : diagnosis and response to corticosteroid therapy", Hepatology, 70, pp.587~596 (2019)
  81. Sarin SK, "Acute-on-chronic liver failure : consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL) : an update", Hepatol Int, 13, pp.353~390 (2019)
  82. Rahim MN, "Acute severe autoimmune hepatitis : corticosteroids or liver transplantation", Liver Transpl, 25, pp.946~959 (2019)
  83. Dyson JK, "Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom", Aliment Pharmacol Ther, 48, pp.951~960 (2018)
  84. Janik MK, "Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life : a prospective, single-centre study", Liver Int, 39, pp.215~221 (2019)
  85. Takahashi A, "Health-related quality of life in patients with autoimmune hepatitis : a questionnaire survey", PLoS One, 13, pp.e0204772~ (2018)
  86. Wong LL, "The impact of autoimmune hepatitis and its treatment on health utility", Hepatology, 68, pp.1487~1497 (2018)

관련 논문AI추천

Recent updates on the management of autoimmune hepatitisAtsumasa Komori대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제1호Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future DirectionsAlbert J. Czaja거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제2호Mycophenolate mofetil as an alternative treatment of autoimmune hepatitis김상현, 류호상, 박승운, 서연석, 심유라, 엄순호, 이한아, 임선영대한간학회 · Clinical and Molecular Hepatology2016 · 제22권 제2호자가면역간염의 진단적 접근박정길, 임기영대한내과학회 · 대한내과학회지2022 · 제97권 제1호Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatmentAtsumasa Komori, Yuki Kugiyama대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity김혜령, 이경분, Eun Ju Cho, Gilhyang Kim, Sook-Hyang Jeong, Soomin Ahn대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제1호

이 간행물의 다른 논문 (17건)

Anxiety and Depression in Patients with Inflammatory Bowel Diseases: The First Step toward Proper ManagementLee Jung Wonpp. 395-396Does the Cytogenetic Analysis Using Fluorescence In Situ Hybridization Improve the Preoperative Diagnostic Accuracy of Pancreatic Ductal Adenocarcinoma?Kim Dong Ukpp. 397-398Risk Factors for Recurrent Colorectal PolypsMiao Qi, Xin He, Ying Zhu, Yuanzhen Hao, Yining Wang, Junbo Hongpp. 399-411A Recent Argument for the Use of Endoscopic Submucosal Dissection for Early Gastric CancersAtsushi Masamune, Takuji Gotoda, Waku Hatta, Tomoyuki Koikepp. 412-422Optimal Endoscopic Treatment and Surveillance of Serrated PolypsVipin Gupta, James E. Eastpp. 423-429
원문 보기